A polymer as an active ingredient in a drug?-?the development of Copolymer 1 as a drug against multiple sclerosis

2002 ◽  
Vol 13 (10-12) ◽  
pp. 859-862 ◽  
Author(s):  
Michael Sela
Keyword(s):  
Multiple Sclerosis ◽  
Active Ingredient ◽  
Copolymer 1

HLA-DRB1*1501 and response to copolymer-1 therapy in relapsing-remitting multiple sclerosis

Neurology ◽  
2001 ◽  
Vol 57 (11) ◽  
pp. 1976-1979 ◽  
Author(s):  
C. Fusco ◽  
V. Andreone ◽  
G. Coppola ◽  
V. Luongo ◽  
F. Guerini ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Relapsing Remitting ◽  
Copolymer 1 ◽  
Remitting Multiple Sclerosis ◽  
Relapsing Remitting Multiple Sclerosis

Development of Copolymer 1 (Copaxone®) as a Specific Drug Against Multiple Sclerosis

1999 ◽  
pp. 191-196 ◽  
Author(s):  
Dvora Teitelbaum ◽  
Rina Aharoni ◽  
Masha Fridkis-Hareli ◽  
Ruth Arnon ◽  
Michael Sela
Keyword(s):  
Multiple Sclerosis ◽  
Specific Drug ◽  
Copolymer 1

The autoimmune reactivity to myelin oligodendrocyte glycoprotein (MOG) in multiple sclerosis is potentially pathogenic: Effect of copolymer 1 on MOG-induced disease

1996 ◽  
Vol 243 (S1) ◽  
pp. S14-S22 ◽  
Author(s):  
Avraham Ben-Nun ◽  
Itzhack Mendel ◽  
Ronit Bakimer ◽  
Masha Fridkis-Hareli ◽  
Dvora Teitelbaum ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Myelin Oligodendrocyte Glycoprotein ◽  
Pathogenic Effect ◽  
Copolymer 1 ◽  
Autoimmune Reactivity

Management of relapsing/remitting multiple sclerosis with copolymer I (Copaxone)

1996 ◽  
Vol 1 (6) ◽  
pp. 325-326 ◽  
Author(s):  
Kenneth P Johnson
Keyword(s):  
Multiple Sclerosis ◽  
Side Effects ◽  
Regulatory Agencies ◽  
Double Blind Trial ◽  
Double Blind ◽  
Relapsing Remitting ◽  
European Regulatory ◽  
Copolymer 1 ◽  
Relapsing Remitting Multiple Sclerosis ◽  
To Receive

Copolymer I (Copaxone) was evaluated in a multicenter, placebo-controlled, double-blind trial at 11 US universities. Two hundred and fifty-one relapsing-remitting ambulatory MS patients were randomized to receive 20 mg of copolymer 1 or placebo by daily subcutaneous injection for approximately 30 months. At conclusion, the copolymer 1 group had 32% fewer relapses (P=0.002) and significantly more were relapse-free (P=0.035). Significantly, more patients were receiving copolymer 1 had improved during the study, while more patients on placebo showed neurological decline (P=0.001). There were few side effects and no drug related laboratory abnormalities. Copolymer 1 is being considered by North American and European regulatory agencies for approval as a commercially available agent for the control of multiple sclerosis.

Humoral and cellular immune responses to Copolymer 1 in multiple sclerosis patients treated with Copaxone®

2001 ◽  
Vol 115 (1-2) ◽  
pp. 152-160 ◽  
Author(s):  
Talma Brenner ◽  
Ruth Arnon ◽  
Michael Sela ◽  
Oded Abramsky ◽  
Zeev Meiner ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Immune Responses ◽  
Cellular Immune Responses ◽  
Copolymer 1 ◽  
Multiple Sclerosis Patients ◽  
Cellular Immune

Treatment of Multiple Sclerosis with Copolymer 1

1996 ◽  
pp. 289-312
Author(s):  
Kenneth P. Johnson ◽  
M. B. Bornstein
Keyword(s):  
Multiple Sclerosis ◽  
Copolymer 1
Sign in / Sign up

Export Citation Format

Share Document